First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
J Clin Oncol
; 41(36): 5505-5511, 2023 Dec 20.
Article
in En
| MEDLINE
| ID: mdl-37910822
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Uterine Cervical Neoplasms
/
Carcinoma, Non-Small-Cell Lung
/
Lung Neoplasms
Limits:
Female
/
Humans
Language:
En
Journal:
J Clin Oncol
Year:
2023
Document type:
Article
Affiliation country:
Azerbaiyán
Country of publication:
Estados Unidos